Treatment of Lung Cancer in Older Patients

Clinics in Chest Medicine

Volumn 28, Issue 4, 2007, Pages 735-749

  Tanoue, Lynn T ^a   Gettinger, Scott ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKULL IRRADIATION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME;

AGED; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 35448947828     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2007.08.003     Document Type: Review

References (104)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
2. Bach P.B., Kattan M.W., Thornquist M.D., et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 95 6 (2003) 470-478
3. Woloshin S., Schwartz L.M., and Welch H.G. Risk charts: putting cancer in context. J Natl Cancer Inst 94 11 (2002) 799-804
4. Peto R., Darby S., Deo H., et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 321 7257 (2000) 323-329
5. Alberg A.J., and Samet J.M. Epidemiology of lung cancer. Chest 123 1 Suppl (2003) 21S-49S
6. Tanoue L., and Matthay R.A. Lung cancer: epidemiology and carcinogenesis. In: Shields T., Locicero J.I., Ponn R., et al. (Eds). General thoracic surgery. 6th edition (2005), Lippincott Williams & Wilkins, Philadelphia 1425-1441
7. Webster's dictionary (1988), Lexicon Publications, Inc., New York
8. Zagonel V., Tirelli U., Serraino D., et al. The aged patient with lung cancer: management recommendations. Drugs Aging 4 1 (1994) 34-46
9. Chan E.D., and Welsh C.H. Geriatric respiratory medicine. Chest 114 6 (1998) 1704-1733
10. Johnson D.H. Small cell lung cancer in the elderly patient. Semin Oncol 24 4 (1997) 484-491
11. Jennens R.R., de Boer R., Irving L., et al. Differences of opinion: a survey of knowledge and bias among clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer. Chest 126 6 (2004) 1985-1993
12. Guadagnoli E., Weitberg A., Mor V., et al. The influence of patient age on the diagnosis and treatment of lung and colorectal cancer. Arch Intern Med 150 7 (1990) 1485-1490
13. National Center for Health Statistics. Health, United States, 2006, with Chartbook on Trends in the Health of Americans (2006), US Government Printing Office, Hyattsville (MD) p. 60-7, 113
14. ECOG performance status. Available at: http://www.ecog.org/general/perf_stat.html. Accessed July 10, 2007.
15. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 6 (1982) 649-655
16. Hurria A., and Kris M.G. Management of lung cancer in older adults. CA Cancer J Clin 53 6 (2003) 325-341
17. Landi F., Zuccala G., Gambassi G., et al. Body mass index and mortality among older people living in the community. J Am Geriatr Soc 47 9 (1999) 1072-1076
18. Eagles J.M., Beattie J.A., Restall D.B., et al. Relation between cognitive impairment and early death in the elderly. BMJ 300 6719 (1990) 239-240
19. Wolfson C., Wolfson D.B., Asgharian M., et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 344 15 (2001) 1111-1116
20. Fukuse T., Satoda N., Hijiya K., et al. Importance of a comprehensive geriatric assessment in prediction of complications following thoracic surgery in elderly patients. Chest 127 3 (2005) 886-891
21. Kris M.G., Giaccone G., Davies A., et al. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J Thorac Oncol 1 9 Suppl (2006) S32-S36
22. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 24 (2006) 2542-2550
23. Lynch T.J., Adjei A.A., Bunn Jr. P.A., et al. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res 12 14 Pt 2 (2006) 4365s-4371s
24. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 10 (2006) 983-991
25. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 6 (1997) 1710-1717
26. Lababede O., Meziane M.A., and Rice T.W. TNM staging of lung cancer: a quick reference chart. Chest 115 1 (1999) 233-235
27. Martini N., Bains M.S., Burt M.E., et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109 1 (1995) 120-129
28. Henschke C.I., Yankelevitz D.F., Libby D.M., et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355 17 (2006) 1763-1771
29. Kato H., Ichinose Y., Ohta M., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 17 (2004) 1713-1721
30. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 25 (2005) 2589-2597
31. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 9 (2006) 719-727
32. Bach P.B., Jett J.R., Pastorino U., et al. Computed tomography screening and lung cancer outcomes. JAMA 297 9 (2007) 953-961
33. Bach P.B. CT screening for lung cancer. N Engl J Med 356 7 (2007) 744
34. Sato M., Saito Y., Endo C., et al. The natural history of radiographically occult bronchogenic squamous cell carcinoma: a retrospective study of overdiagnosis bias. Chest 126 1 (2004) 108-113
35. Motohiro A., Ueda H., Komatsu H., et al. Prognosis of non-surgically treated, clinical stage I lung cancer patients in Japan. Lung Cancer 36 1 (2002) 65-69
36. Sobue T., Suzuki T., Matsuda M., et al. Survival for clinical stage I lung cancer not surgically treated: comparison between screen-detected and symptom-detected cases. The Japanese Lung Cancer Screening Research Group. Cancer 69 3 (1992) 685-692
37. Beckles M.A., Spiro S.G., Colice G.L., et al. The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest 123 1 Suppl (2003) 105S-114S
38. Wyser C., Stulz P., Soler M., et al. Prospective evaluation of an algorithm for the functional assessment of lung resection candidates. Am J Respir Crit Care Med 159 5 Pt 1 (1999) 1450-1456
39. Mery C.M., Pappas A.N., Bueno R., et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest 128 1 (2005) 237-245
40. Peake M.D., Thompson S., Lowe D., et al. Ageism in the management of lung cancer. Age Ageing 32 2 (2003) 171-177
41. O'Rourke M.A., Feussner J.R., Feigl P., et al. Age trends of lung cancer stage at diagnosis. Implications for lung cancer screening in the elderly. JAMA 258 7 (1987) 921-926
42. Trimble E.L., Carter C.L., Cain D., et al. Representation of older patients in cancer treatment trials. Cancer 74 7 Suppl (1994) 2208-2214
43. Turner N.J., Haward R.A., Mulley G.P., et al. Cancer in old age: is it inadequately investigated and treated?. BMJ 319 7205 (1999) 309-312
44. Cerfolio R.J., and Bryant A.S. Survival and outcomes of pulmonary resection for non-small cell lung cancer in the elderly: a nested case-control study. Ann Thorac Surg 82 2 (2006) 424-429 [discussion: 9-30]
45. Teeter S.M., Holmes F.F., and McFarlane M.J. Lung carcinoma in the elderly population: influence of histology on the inverse relationship of stage to age. Cancer 60 6 (1987) 1331-1336
46. Bernet F., Brodbeck R., Guenin M.O., et al. Age does not influence early and late tumor-related outcome for bronchogenic carcinoma. Ann Thorac Surg 69 3 (2000) 913-918
47. Mahoney F.I., and Barthel D.W. Functional evaluation: the Barthel Index. Md State Med J 14 (1965) 61-65
48. Sainsbury A., Seebass G., Bansal A., et al. Reliability of the Barthel Index when used with older people. Age Ageing 34 3 (2005) 228-232
49. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 3 (1975) 189-198
50. Crum R.M., Anthony J.C., Bassett S.S., et al. Population-based norms for the mini-mental state examination by age and educational level. JAMA 269 18 (1993) 2386-2391
51. Holsinger T., Deveau J., Boustani M., et al. Does this patient have dementia?. JAMA 297 21 (2007) 2391-2404
52. Zagonel V. Importance of a comprehensive geriatric assessment in older cancer patients. Eur J Cancer 37 Suppl 7 (2001) S229-S233
53. Repetto L., Fratino L., Audisio R.A., et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 20 2 (2002) 494-502
54. van Rens M.T., de la Riviere A.B., Elbers H.R., et al. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117 2 (2000) 374-379
55. Jazieh A.R., Hussain M., Howington J.A., et al. Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. Ann Thorac Surg 70 4 (2000) 1168-1171
56. Ginsberg R.J., Hill L.D., Eagan R.T., et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 86 5 (1983) 654-658
57. Damhuis R.A., and Schutte P.R. Resection rates and postoperative mortality in 7,899 patients with lung cancer. Eur Respir J 9 1 (1996) 7-10
58. Fan J., Wang X.J., Jiang G.N., et al. Survival and outcomes of surgical treatment of the elderly NSCLC in China: a retrospective matched cohort study. Eur J Surg Oncol 33 5 (2007) 639-643
59. Sullivan V., Tran T., Holmstrom A., et al. Advanced age does not exclude lobectomy for non-small cell lung carcinoma. Chest 128 4 (2005) 2671-2676
60. Yamamoto K., Alarcon J., Medina V., et al. Surgical results of stage I non-small cell lung cancer: comparison between elderly and younger patients. Eur J Cardiothorac Surg 23 (2003) 21-25
61. Sawada S., Komori E., Nogami N., et al. Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition. Chest 128 3 (2005) 1557-1563
62. Haffty B.G., Goldberg N.B., Gerstley J., et al. Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 15 1 (1988) 69-73
63. Sibley G.S. Radiotherapy for patients with medically inoperable stage I non-small cell lung carcinoma: smaller volumes and higher doses: a review. Cancer 82 3 (1998) 433-438
64. Perez C.A., Pajak T.F., Rubin P., et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. Cancer 59 11 (1987) 1874-1881
65. Decker R.H., Tanoue L.T., Colasanto J.M., et al. Evaluation and definitive management of medically inoperable early-stage non-small-cell lung cancer. Part 1: assessment and conventional radiotherapy. Oncology (Williston Park) 20 7 (2006) 727-736
66. Decker R.H., Tanoue L.T., Colasanto J.M., et al. Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities. Oncology (Williston Park) 20 8 (2006) 899-905 [discussion: 8, 13]
67. Steinke K., Sewell P.E., Dupuy D., et al. Pulmonary radiofrequency ablation: an international study survey. Anticancer Res 24 1 (2004) 339-343
68. VanSonnenberg E., Shankar S., Morrison P.R., et al. Radiofrequency ablation of thoracic lesions, part 2. Initial clinical experience: technical and multidisciplinary considerations in 30 patients. AJR Am J Roentgenol 184 2 (2005) 381-390
69. Potters L., Steinberg M., Rose C., et al. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 60 4 (2004) 1026-1032
70. Hiraoka M., and Nagata Y. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the Japanese experience. Int J Clin Oncol 9 5 (2004) 352-355
71. Onishi H., Araki T., Shirato H., et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101 7 (2004) 1623-1631
72. Wulf J., Haedinger U., Oppitz U., et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 60 1 (2004) 186-196
73. Strauss G., Herndon J., Maddaus M., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. ASCO Meeting Abstracts 24 18 Suppl (2006) 7007
74. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 4 (2004) 351-360
75. Pepe C., Hasan B., Winton T.L., et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR 10. J Clin Oncol 25 12 (2007) 1553-1561
76. Fruh M., Tribodet H., Pignon J.P., et al. A pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 (2007) 18S
77. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88 17 (1996) 1210-1215
78. Sause W., Kolesar P., Taylor S.I., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 2 (2000) 358-364
79. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 9 (1999) 2692-2699
80. Curran W., Scott C., and Langer C. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: RTOG 9410. Proceedings of the American Society of Clinical Oncology 22 (2003) 621a
81. Langer C., Hsu C., and Curran W. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 9410. Proceedings of the American Society of Clinical Oncology 21 (2002) 299a
82. Rocha Lima C.M., Herndon II J.E., Kosty M., et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 94 1 (2002) 181-187
83. Schild S.E., Stella P.J., Geyer S.M., et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54 2 (2002) 370-378
84. Sgroi M., Neubauer M., Ansari R., et al. An analysis of elderly patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (C) vs observation (O) in pts with stage III non small cell lung cancer (NSCLC). ASCO Meeting Abstracts 25 18 Suppl (2007) 9037
85. Atagi S., Kawahara M., Tamura T., et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol 35 4 (2005) 195-201
86. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 2 (2002) 92-98
87. Lilenbaum R.C., Herndon II J.E., List M.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 23 1 (2005) 190-196
88. Sederholm C., Hillerdal G., Lamberg K., et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 23 33 (2005) 8380-8388
89. Langer C., Vangel M., Schiller J.H., et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 YRS) with NSCLC do as well as young pts (<70). Proceedings of the American Society of Clinical Oncology 22 (2003) 2572
90. Ramalingam S., Dahlberg S., Langer C., et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (V) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. ASCO Meeting Abstracts 25 Suppl 18 (2007) 7535
91. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 6 Suppl 1 (2001) 4-7
92. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91 1 (1999) 66-72
93. Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 5 (2003) 362-372
94. Kudoh S., Takeda K., Nakagawa K., et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24 22 (2006) 3657-3663
95. Simon G.R., and Wagner H. Small cell lung cancer. Chest 123 1 Suppl (2003) 259S-271S
96. Pignon J.P., Arriagada R., Ihde D.C., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 23 (1992) 1618-1624
97. Turrisi III A.T., Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 4 (1999) 265-271
98. Yuen A.R., Zou G., Turrisi A.T., et al. Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 89 9 (2000) 1953-1960
99. Schild S.E., Bonner J.A., Shanahan T.G., et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 59 4 (2004) 943-951
100. Schild S.E., Stella P.J., Brooks B.J., et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 103 11 (2005) 2349-2354
101. Okamoto H., Watanabe K., Kunikane H., et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97 2 (2007) 162-169
102. Ardizzoni A., Favaretto A., Boni L., et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis. A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 23 3 (2005) 569-575
103. Auperin A., Arriagada R., Pignon J.P., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission: Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341 7 (1999) 476-484
104. Slotman B., Faivre-Finn C., Kramer G., et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357 7 (2007) 664-672